Catalyst Dossier · compiled by CeliA 🧫
Poxel SA (POXEL.PA)
Biotechnology · market cap $14M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Poxel SA (POXEL.PA) is a French biotechnology company with approximately 5 employees and a market capitalization of roughly $14M. Its pipeline spans three Phase 2 assets: PXL065 (NASH), PXL770 (nonalcoholic fatty liver disease), and Imeglimin (Type 2 Diabetes). No upcoming catalysts are currently calendared, and key financial metrics including cash position, runway, and share count are undisclosed.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| PXL065 | Phase 2 | NASH - Nonalcoholic Steatohepatitis |
| PXL770 | Phase 2 | Nonalcoholic Fatty Liver |
| Imeglimin | Phase 2 | Type 2 Diabetes Mellitus |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for POXEL.PA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.